loadpatents
Patent applications and USPTO patent grants for Frewin; Mark Raymond.The latest application filed is for "therapeutic antibodies".
Patent | Date |
---|---|
Therapeutic Antibodies App 20210269544 - WALDMANN; Herman ;   et al. | 2021-09-02 |
Therapeutic antibodies Grant 10,800,850 - Waldmann , et al. October 13, 2 | 2020-10-13 |
Therapeutic Antibodies App 20170137529 - Waldmann; Herman ;   et al. | 2017-05-18 |
Therapeutic Antibodies App 20140212418 - Waldmann; Herman ;   et al. | 2014-07-31 |
Therapeutic antibodies Grant 8,623,357 - Waldmann , et al. January 7, 2 | 2014-01-07 |
Therapeutic antibodies with reduced side effect App 20130028893 - Waldmann; Herman ;   et al. | 2013-01-31 |
Therapeutic antibodies App 20100015166 - Waldmann; Herman ;   et al. | 2010-01-21 |
Therapeutic antibodies Grant 7,465,790 - Waldmann , et al. December 16, 2 | 2008-12-16 |
Therapeutic antibodies App 20040258677 - Waldmann, Herman ;   et al. | 2004-12-23 |
Therapeutic antibodies with reduced side effect App 20040109855 - Waldmann, Herman ;   et al. | 2004-06-10 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.